

GeNotes: a new online ‘just in time’ genomics resource for healthcare professionals

Authors: Ellen Copson,^A Terri McVeigh,^B Amy Frost^C and Kate Tatton-Brown^D

Introduction

Advances in DNA sequencing technologies have transformed the care of many patients with cancer. Systemic anti-cancer therapies are increasingly targeted against aberrant proteins associated with key driver mutations within the tumour (somatic) genome, requiring testing for, and identification of, such alterations in tumour-derived DNA to confer eligibility for treatment.¹ Falling sequencing costs have also driven expansion in testing for constitutional (germline) variants in cancer susceptibility genes (CSGs), which may inform surgical, systemic and radio-therapeutic options, as well as future cancer risks for patients and their relatives.²

NHS England’s publication of genomic test directories for cancer and rare and inherited disease, (including heritable cancer syndromes), aims to improve patients’ access to genomic tests while streamlining testing processes.^{3,4} However, studies have indicated that integration of genomic data into ‘mainstream’ care is currently limited by clinicians’ genomic literacy.^{5–8}

GeNotes is a new online ‘just in time’ educational resource for clinicians, it is being developed across specialties in collaboration with Health Education England’s Genomic Education Programme. It aims to improve use of genomic testing by providing clinical information about specific tests, underpinned by opportunities to access broader genomics education. In order to provide education at the point of oncology care, an oncogenomics working group was established.

Methods

Specialist trainees in clinical genetics and oncology were recruited to produce tiered resources on genomic topics relevant to cancer patients’ clinical care. ‘In the clinic’ documents are written to a strict template around a specific clinical scenario, providing concise advice on when, what, how, and by whom genetic testing should be undertaken, as well as management of results. Each ‘In the clinic’ resource links to underpinning ‘Knowledge hub’ documents, which include detailed information about genetic and oncological conditions, and genomic

principles and technologies. All genomic test information is linked to appropriate pages of the NHS genomic test directories.^{3,4} Sections on resources for clinicians and patients signpost key references and additional educational resources.

Resources are reviewed by oncogenomics experts prior to uploading onto a purpose-built platform. Private beta phase testing (moderated usability testing, feedback questionnaire, follow-up interviews and website analytics review) of the first wave of resources was completed in November 2021 by Lagom Strategy.

Results

Nineteen ‘In the clinic’ and 20 ‘Knowledge hub’ resources have so far been produced. Private beta phase testing (n=21) indicated high user satisfaction, with 95.2% reporting that they would be likely / very likely to use GeNotes in the future and 95.2% also stating that they would be likely / very likely to recommend GeNotes to other practitioners. GeNotes scored highly (90%) on system usability score. Current resources are being refined according to beta testing feedback. Additional resources are in development.

Conclusion

Appropriate and effective use of genomic information in the care of cancer patients requires that clinicians are sufficiently versed and confident in using genomic tests.⁹ GeNotes is one of Health Education England Genomic Education Programme’s flagship initiatives. The GeNotes oncogenomics working group is spearheading integration of the resource into mainstream care. Initial evaluation indicates that GeNotes will provide a valuable and practical educational resource for clinicians. ■

Funding statement

Work is funded by Health Education England.

References

- 1 Baird R, Banks I, Cameron D *et al.* An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. *Ecancermedicalscience* 2016;10:608.
- 2 Tutt ANJ, Garber JE, Kaufman B *et al.* Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *N Engl J Med* 2021;384:2394–2405.

Authors: ^AUniversity of Southampton, Southampton, UK; ^BRoyal Marsden NHS Foundation Trust, London, UK; ^CHealth Education England, London, UK; ^DSt George’s University Hospitals NHS Foundation Trust, London, UK and Health Education England, London, UK

- 3 National Genomic Test Directory for Rare and Inherited Disease. NHS England. www.england.nhs.uk/publication/national-genomic-test-directories [Accessed 5 February 2022].
- 4 National Genomic Test Directory for Cancer. NHS England. www.england.nhs.uk/publication/national-genomic-test-directories/ [Accessed 5 February 2022].
- 5 Brierley KL, Blouch E, Cogswell W *et al.* Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. *Cancer J* 2012;18:303–9.
- 6 Eccles BK, Copson E, Maishman T *et al.* Understanding of BRCA VUS genetic results by breast cancer specialists. *BMC Cancer* 2015;15:936.
- 7 Al Bakir I, Sebepos-Rogers GM, Burton H *et al.* Mainstreaming of genomic medicine in gastroenterology, present and future: a nationwide survey of UK gastroenterology trainees. *BMJ Open* 2019;9:e030505.
- 8 McHugh JK, Offiah G, Daly S *et al.* Postgraduate training in cancer genetics – a cross-specialty survey exploring experience of clinicians in Ireland. *Ir J Med Sci* 2021;30:1–8.
- 9 McGrath S, Ghersi D. Building towards precision medicine: empowering medical professionals for the next revolution. *BMC Med Genomics* 2016;9:23.